Psychotropic medication use in pediatric patients with cancer

Archives of Pediatrics and Adolescent Medicine

Volumn 160, Issue 8, 2006, Pages 818-822

  Pao, Maryland ^a   Ballard, Elizabeth D ^a   Rosenstein, Donald L ^a   Wiener, Lori ^b   Wayne, Alan S ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; CLONIDINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

ADOLESCENT; ADULT; ARTICLE; BRAIN TUMOR; CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; INFANT; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOMA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; MALE; MENTAL DISORDERS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 33746910175     PISSN: 10724710     EISSN: 10724710     Source Type: Journal    
DOI: 10.1001/archpedi.160.8.818     Document Type: Article

References (36)

1. National Center for Health Statistics. Leading causes of death for 2001. http://www.cdc.gov/nchs/data/dvs/LCWK1_2001.pdf. Accessed October 14, 2005.
2. Surveillance Epidemiology and End Results, National Cancer Institute. SEER Cancer Statistics Review, 1975-2002. http://seer.cancer.gov/csr/1975_2002/. Accessed November 14, 2005.
3. Conrad P. Prescribing more psychotropic medications for children: what does the increase mean? Arch Pediatr Adolesc Med. 2004;158:829-830.
4. Jellinek MS. Mirror, mirror on the wall: are we prescribing the right psychotropic medications to the right children using the right treatment plan? Arch Pediatr Adolesc Med. 2003;157:14-16.
5. Walkup JT. Increasing use of psychotropic medications in children and adolescents: what does it mean? J Child Adolesc Psychopharmacol. 2003;13:1-3.
6. Vitiello B. Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics. 2001;108:983-989.
7. Zito JM, Safer DJ, Dosreis S, et al. Psychotropic practice patterns for youth: a 10 year perspective. Arch Pediatr Adolesc Med. 2003;157:17-25.
8. Mental Health: A report of the Surgeon General. http://www. surgeongeneral.gov/library/mentalhealth/chapter3/sec3.html. Accessed November 18, 2005.
9. Kersun LS, Kazak AE. Prescribing practices of selective serotonin reuptake inhibitors (SSRIs) among pediatric oncologists: a single institution experience [published online ahead of print]. Pediatr Blood Cancer. http://www3.interscience.wiley.com/cgi-bin/fulltext/110560614/PDFSTART. Accessed November 30, 2005.
10. Bealke JM, Meighen KG. Risperidone treatment of three seriously medically ill children with secondary mood disorders. Psychosomatics. 2005;46:254-258.
11. Pelletier G. Lacroix Y, Moghrabi A, Robaey P. Double-blind crossover study of chlorpromazine and lorazepam in the treatment of behavioral problems during treatment of children with acute lymphoblastic leukemia receiving glucocorticoids. Med Pediatr Oncol. 2000;34:276-277.
12. Brown RL, Henke A, Greenhalgh DG, Warden GD. The use of haloperidol in the agitated, critically ill pediatric patient with burns. J Burn Care Rehabil. 1996;17:34-38.
13. Pfefferbaum B, Overall JE, Boren HA, Frankel LS, Sullivan MP, Johnson K. Alprazolam in the treatment of anticipatory and acute situational anxiety in children with cancer. J Am Acad Child Adolesc Psychiatry. 1987;26:532-535.
14. Maisami M, Sohmer BH, Coyle JT. Combined use of tricyclic antidepressants and neuroleptics in the management of terminally ill children: a report on three cases. J Am Acad Child Psychiatry. 1985;24:487-489.
15. Pfefferbaum-Levine B, Kumor K, Cangir A, Choroszy M, Roseberry EA. Tricyclic antidepressants for children with cancer. Am J Psychiatry. 1983;140:1074-1076.
16. Holland JC. IPOS Sutherland Memorial Lecture. An international perspective on the development of psychosocial oncology: overcoming cultural and attitudinal barriers to improve psychosocial care. Psychooncology. 2004;13:445-459.
17. Derogatis LR, Feldstein M, Morrow G, et al. A survey of psychotropic drug prescriptions in an oncology population. Cancer. 1979;44:1919-1920.
18. Cullivan R, Crown J, Walsh N. The use of psychotropic medication in patients referred to a psycho-oncology service. Psychooncology. 1998;7:301-306.
19. Fisch M. Treatment of depression in cancer. J Natl Cancer Inst Monogr. 2004;(32):105-111.
20. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? a cytokine-immunologic model of cancer symptoms. Cancer. 2003;97:2919-2925.
21. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11:279-292.
22. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med. 2001;344:961-966.
23. Gothelf D, Rubinstein M, Shemesh E, et al. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer. J Am Acad Child Adolesc Psychiatry. 2005;44:1258-1262.
24. Shemesh E, Bartell A, Newcorn JH. Assessment and treatment of depression in medically ill children. Curr Psychiatry Rep. 2002;4:88-92.
25. Bennett DS. Depression among children with chronic medical problems: a meta-analysis. J Pediatr Psychol. 1994;19:149-169.
26. Shemesh E, Yehuda R, Rockmore L, et al. Assessment of depression in medically ill children presenting to pediatric specialty clinics. J Am Acad Child Adolesc Psychiatry. 2005;44:1249-1257.
27. Harris ES, Canning RD, Kelleher KJ. A comparison of measures of adjustment, symptoms, and impairment among children with chronic medical conditions. J Am Acad Child Adolesc Psychiatry. 1996;35:1025-1032.
28. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry. 1999;38:557-565.
29. Cummings MR, Miller BD. Pharmacologic management of behavioral instability in medically ill pediatric patients. Curr Opin Pediatr. 2004;16:516-522.
30. Keskinbora K, Pekel AF, Aydinli I. The use of gabapentin in a 12-year old boy with cancer pain. Acta Anaesthesiol Scand. 2004;48:663-664.
31. Bhangoo RK, Lowe CH, Myers FS, et al. Medication use in children and adolescents treated in the community for bipolar disorder. J Child Adolesc Psychopharmacol. 2003;13:515-522.
32. Wolfe J, Grier HE, Klar N et al. Symptoms and suffering at the end of life in children with cancer. N Engl J Med. 2000;342:326-333.
33. Fleishman SB. Treatment of symptom clusters: pain, depression and fatigue. J Natl Cancer Inst Monogr. 2004;(32):119-123.
34. Rosack J. New data show declines in antidepressant prescribing. Psychiatr News. 2005;40:1-39.
35. Vitiello B. Pediatric psychopharmacology and the interaction between drugs and the developing brain. Can J Psychiatry. 1998;43:582-584.
36. Buclin T, Mazzocato C, Berney A, Stiefel F. Psychopharmacology in supportive care of cancer: a review for the clinician, IV: other psychotropic agents. Support Care Cancer. 2001;9:213-222.